Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. BB Biotech AG
  6. News
  7. Summary
    BION   CH0038389992

BB BIOTECH AG

(BION)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE: Solid second quarter for the -2-

07/23/2021 | 01:01am EDT
to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and 
its directors and officers accept no responsibility in that regard. All forward-looking statements included in this 
release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation 
to update any forward-looking statements as a result of new information, future events or other factors. 
Composition of BB Biotech's portfolio as at June 30, 2021 
(in % of securities, rounded values) 
Moderna                                    12.2% 
Ionis Pharmaceuticals                       7.7% 
Argenx SE                                   6.1% 
Neurocrine Biosciences                      6.0% 
Incyte                                      5.2% 
Agios Pharmaceuticals                       5.0% 
 
Fate Therapeutics                           4.7% 
Vertex Pharmaceuticals                      4.5% 
Alnylam Pharmaceuticals                     4.0% 
Biogen                                      3.7% 
Macrogenics                                 3.6% 
Arvinas                                     3.6% 
Crispr Therapeutics                         3.3% 
Intra-Cellular Therapies                    3.0% 
Radius Health                               2.9% 
Sage Therapeutics                           2.8% 
Myovant Sciences                            2.5% 
Relay Therapeutics                          2.0% 
Esperion Therapeutics                       2.0% 
Beam Therapeutics                           1.7% 
Molecular Templates                         1.6% 
Essa Pharma                                 1.5% 
Generation Bio Co.                          1.4% 
Scholar Rock Holding                        1.4% 
Halozyme Therapeutics                       1.3% 
Revolution Medicines                        1.2% 
Exelixis                                    1.1% 
Nektar Therapeutics                         1.0% 
Black Diamond Therapeutics                  0.9% 
Mersana Therapeutics                        0.8% 
Kezar Life Sciences                         0.5% 
Wave Life Sciences                          0.4% 
Homology Medicines                          0.3% 
 
Alder Biopharmaceuticals - CVR              0.1% 
 
Total securities                  CHF 4 349.3 mn 
 
Other assets                          CHF 7.8 mn 
Other liabilities                 CHF (310.1) mn 
 
Net Asset Value                   CHF 4 047.0 mn 
 ----------------------------------------------------------------------------------------------------------------------- 

2021-07-23 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      BB BIOTECH AG 
              Schwertstrasse 6 
              8200 Schaffhausen 
              Switzerland 
Phone:        +41 52 624 08 45 
E-mail:       info@bbbiotech.com 
Internet:     www.bbbiotech.ch 
ISIN:         CH0038389992 
WKN:          A0NFN3 
Listed:       Regulated Market in Frankfurt (Prime Standard); Mailand, SIX 
EQS News ID:  1220898 
 
End of News   DGAP News Service 
=------------ 

1220898 2021-07-23

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1220898&application_name=news 
 

(END) Dow Jones Newswires

July 23, 2021 01:00 ET (05:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
ARGENX SE -2.63% 262.9 Real-time Quote.11.57%
ARVINAS, INC. -5.92% 88.61 Delayed Quote.10.90%
BB BIOTECH AG 0.00% 88.05 Delayed Quote.18.75%
BIOGEN INC. -0.51% 291.71 Delayed Quote.18.16%
DJ INDUSTRIAL 0.10% 34798 Delayed Quote.11.93%
EXELIXIS, INC. -0.73% 20.35 Delayed Quote.2.14%
INCYTE CORPORATION -1.12% 69 Delayed Quote.-19.99%
MODERNA, INC. -5.38% 430.14 Delayed Quote.335.15%
VERTEX, INC. 0.11% 19.02 Delayed Quote.-45.48%
All news about BB BIOTECH AG
07/29EQS-ADHOC : Bellevue's bottom-line profit quadruples to CHF 22.5 mn - assets under managem..
DJ
07/23Bb Biotech Ag Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
07/23BB BIOTECH : Posts Lower H1 Profit, Operating Income
MT
07/23BB BIOTECH : Interim report as at June 30, 2021
PU
07/23BB BIOTECH : publishes its interim report
EQ
07/23BB BIOTECH : Solid second quarter for the biotech industry - BB Biotech raised its allocat..
EQ
07/23DGAP-ADHOC : BB Biotech AG pubblica il proprio rapporto intermedio
DJ
07/23DGAP-ADHOC : BB Biotech AG publishes its interim report
DJ
07/23DGAP-NEWS : Il settore delle biotecnologie -2-
DJ
07/23DGAP-NEWS : Il settore delle biotecnologie archivia un secondo trimestre all'insegna della..
DJ
More news
Analyst Recommendations on BB BIOTECH AG
More recommendations
Financials
Sales 2021 130 M 141 M 141 M
Net income 2021 439 M 475 M 475 M
Net Debt 2021 23,5 M 25,3 M 25,3 M
P/E ratio 2021 8,66x
Yield 2021 4,57%
Capitalization 4 878 M 5 279 M 5 272 M
EV / Sales 2021 37,7x
EV / Sales 2022 19 605x
Nbr of Employees 10
Free-Float 98,2%
Chart BB BIOTECH AG
Duration : Period :
BB Biotech AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BB BIOTECH AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 88,05 CHF
Average target price 95,50 CHF
Spread / Average Target 8,46%
EPS Revisions
Managers and Directors
Michael Hutter Head-Finance & Compliance
Erich Hunziker Chairman-Supervisory Board
Daniel Koller Head-Investment Management
Clive A. Meanwell Vice Chairman-Supervisory Board
Thomas von Planta Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BB BIOTECH AG18.75%5 279
MODERNA, INC.335.15%183 498
LONZA GROUP AG33.58%61 085
IQVIA HOLDINGS INC.46.38%50 254
CELLTRION, INC.-20.75%33 124
SEAGEN INC.-5.09%30 241